Carfilzomib (PR-171)
中文名称:卡非佐米
目录号:S2853 Purity: 99.75%
Carfilzomib (PR-171) 是一种不可逆proteasome抑制剂,在ANBL-6细胞中IC50为<5 nM,在体外优先抑制β5亚基的ChT-L活性,对PGPH和T-L活性很弱或没有作用。Carfilzomib 可激活自噬并诱导细胞凋亡。
CAS: 868540-17-4
客户使用Selleck的Carfilzomib (PR-171)发表文献226篇
- Nature, 2024 626(8000):874-880
- J Hematol Oncol, 2024 17(1):85
- Cell Discov, 2023 9(1):47
- Cancer Cell, 2021 S1535-6108(20)30609-7
- Nature, 2020 579(7797):136-140
- Nat Immunol, 2020 10.1038/s41590-020-0697-2
- Blood, 2020 18 pii: blood
- Cell, 2019 36(2):179-193
- Cancer Cell, 2019 36(2):179-193
- Cancer Cell, 2019 35(5):752-766
- Cancer Cell, 2019 36(5):498-511
- Nat Med, 2018 24(3):292-303
- J Hematol Oncol, 2018 11(1):112
- Cell Host Microbe, 2017 22(4):507-518
- Blood, 2017 5;129(1):88-99
- Nat Cell Biol, 2016 18(8):897-909
- Nat Med, 2015 10.1038/nm.3855
- Cancer Discov, 2015 5(9):972-87
- Blood, 2015 125(2):407-10
- Blood, 2015 10.1182/blood-2015-04-639542
- Blood, 2015 24;126(13):1565-74
- Blood, 2014 123(26):4120-31
- Nat Commun, 2024 15(1):2207
- Nat Commun, 2024 15(1):8485
- Nat Commun, 2024 15(1):9667
- Nat Commun, 2024 15(1):2485
- Mol Cell, 2024 84(23):4612-4628.e13
- Cell Rep Med, 2024 5(10):101752
- J Exp Clin Cancer Res, 2024 43(1):68
- J Immunother Cancer, 2024 12(11)e009805
- Cell Death Dis, 2024 15(8):588
- J Transl Med, 2024 22(1):208
- Front Immunol, 2024 15:1470328
- iScience, 2024 27(2):109015.
- iScience, 2024 27(5):109814
- Oncotarget, 2024 15:159-174
- Cancers (Basel), 2024 16(11)2139
- Cancers (Basel), 2024 16(23)3963
- Sci Rep, 2024 14(1):19288
- bioRxiv, 2024 2024.03.27.587011
- Cancer Res Commun, 2024 4(10):2685-2698
- bioRxiv, 2024 2024.03.29.587346
- Cancer Lett, 2023 565:216218
- Cell Death Dis, 2023 14(3):213
- Cell Death Dis, 2023 14(1):42
- Cell Rep, 2023 42(3):112230
- Blood Adv, 2023 7(14):3485-3500
- Blood Adv, 2023 7(4):469-481
- iScience, 2023 26(8):107302
- Biochem Pharmacol, 2023 208:115387
- Int J Mol Sci, 2023 24(17)13303
- Cancers (Basel), 2023 15(8)2199
- Front Oncol, 2023 13:1197542
- Pharmaceuticals (Basel), 2023 16(8)1181
- Biosci Rep, 2023 43(1)BSR20222102
- Microbiol Spectr, 2023 10.1128/spectrum.01904-23
- Sci Adv, 2023 9(41):eade3816
- Sci Adv, 2023 9(25):eade7890
- bioRxiv, 2023 2023.09.15.557918
- Res Sq, 2023 rs.3.rs-3112163
- Nat Commun, 2022 13(1):2736
- Nat Commun, 2022 13(1):6226
- Mol Cell, 2022 82(3):585-597.e11
- Cell Death Differ, 2022 10.1038/s41418-022-00942-z
- EMBO J, 2022 41(20):e110871
- Haematologica, 2022 107(4):947-957
- Cell Death Dis, 2022 13(3):197
- Cell Rep, 2022 40(13):111428
- JCI Insight, 2022 7(19)e157081
- Aging Cell, 2022 21(3):e13556
- Elife, 2022 11e76100
- Elife, 2022 11e82860
- Front Immunol, 2022 13:832989
- Cells, 2022 11(15)2331
- Cells, 2022 11(5)838
- Biochem Pharmacol, 2022 197:114913
- Front Pharmacol, 2022 13:856804
- Am J Cancer Res, 2022 12(7):3280-3293
- Cancers (Basel), 2022 14(19)4883
- Mol Neurobiol, 2022 10.1007/s12035-021-02687-1
- Biomedicines, 2022 10(7)1638
- Sci Rep, 2022 12(1):10616
- J Cell Biochem, 2022 10.1002/jcb.30213
- J Clin Med, 2022 11-195549
- PLoS One, 2022 17(12:e0274704)
- Cancer Chemother Pharmacol, 2022 89(5):643-653
- Sci Adv, 2022 8(39):eabq5575
- Cancer Res Commun, 2022 2(12):1693-1710
- Nat Commun, 2021 12(1):2522
- Autophagy, 2021 1-14
- J Control Release, 2021 S0168-3659(21)00126-7
- Haematologica, 2021 10.3324/haematol.2021.278743
- Cell Death Dis, 2021 12(7):624
- Cell Rep, 2021 34(11):108870
- EMBO Rep, 2021 e52101
- Blood Adv, 2021 bloodadvances.2020003820
- Hemasphere, 2021 5(7):e602
- Mol Cancer Ther, 2021 20(2):367-378
- Int J Mol Sci, 2021 22(13)7114
- Int J Mol Sci, 2021 22(3)1341
- J Am Heart Assoc, 2021 10(24):e022247
- J Cell Mol Med, 2021 10.1111/jcmm.16953
- Cancers (Basel), 2021 13(4)843
- Neoplasia, 2021 24(1):1-11
- Front Oncol, 2021 11:631594
- Biomedicines, 2021 9(6)627
- Sci Rep, 2021 11(1):2074
- Oncol Rep, 2021 45(4)34
- Sci Adv, 2021 7(23)eabg2697
- Nat Commun, 2020 22;11(1):1931
- Adv Sci (Weinh), 2020 7(23):2001914
- Adv Sci (Weinh), 2020 7(22):2002747
- Nat Chem Biol, 2020 10.1038/s41589-020-0594-x
- Autophagy, 2020 10.1080/15548627.2020.1740529
- Autophagy, 2020 1-13
- Blood Cancer J, 2020 10(12):125
- Clin Cancer Res, 2020 clincanres.1232.2020
- Proc Natl Acad Sci U S A, 2020 117(33):20004-20014
- Mol Syst Biol, 2020 16(6):e9596
- Br J Cancer, 2020 10.1038/s41416-020-01191-y
- Cell Rep, 2020 32(2):107897
- Acta Pharmacol Sin, 2020 10.1038/s41401-020-00544-w
- Oncogene, 2020 9
- Cell Mol Life Sci, 2020 10.1007/s00018-020-03568-x
- Blood Adv, 2020 4(18):4312-4326
- Front Immunol, 2020
- Int J Cancer, 2020 10.1002/ijc.33046
- Int J Cancer, 2020 10.1002/ijc.32976
- Cancer Sci, 2020 111(4):1279-1290
- Oncotarget, 2020 11(44):3984-3997
- Cancers (Basel), 2020 11;12(5):E1207
- J Zhejiang Univ Sci B, 2020 21(1):64-76
- Eur J Pharmacol, 2020 870:172821
- FASEB J, 2020 34(9):12379-12391
- J Electroanal Chem (Lausanne), 2020 878:114733
- SLAS Discov, 2020 19;2472555220915851
- Mol Biol Rep, 2020 47(6):4849-4856
- G3 (Bethesda), 2020 4;10(5):1585-1597
- Iran J Pharm Res, 2020 19(1):153-165
- Neurooncol Adv, 2020 2(1):vdaa051
- DASH, 2020 None
- Mol Cell, 2019 75(4):849-858
- Nat Chem Biol, 2019 15(3):232-240
- Leukemia, 2019 10.1038/s41375-019-0525-6
- EMBO Mol Med, 2019 11(10):e9930
- Cell Death Dis, 2019 10(8):611
- Cell Rep, 2019 28(12):3224-3237
- Cell Chem Biol, 2019 10.1016/j.chembiol.2019.10.013
- Cell Chem Biol, 2019 26(3):340-351
- Apoptosis, 2019 24(5-6):404-413
- PLoS Pathog, 2019 15(1):e1007498
- Biochim Biophys Acta Mol Basis Dis, 2019 1865(6):1666-1676
- Arch Toxicol, 2019 93(4):953-964
- Mol Cancer Ther, 2019 18(11):2097-2110
- Int J Mol Sci, 2019 20(24)
- Amyloid, 2019 26(1):24-33
- Cancers (Basel), 2019 11(7)
- Mol Cancer Res, 2019 17(12):2444-2456
- Sci Rep, 2019 9(1):18409
- Sci Rep, 2019 9(1):18062
- Cell Physiol Biochem, 2019 53(6):999-1014
- Biochem J, 2019 476(21):3211-3226
- PLoS One, 2019 14(12):e0225727
- Cancer Lett, 2018
- Cell Death Dis, 2018 9(2):162
- Mol Cancer Ther, 2018 17(12):2610-2621
- Int J Mol Sci, 2018 19(6)E1551
- FEBS J, 2018 285(3):467-480
- Oncotarget, 2018
- Oncotarget, 2018 9(29):20265-20281
- Ann Hematol, 2018 97(5):839-849
- Hum Mol Genet, 2018 27(3):451-462
- SLAS Discov, 2018 23(5):459-473
- Nat Commun, 2017 8:14290
- Exp Mol Med, 2017 49(8):e365
- Clin Cancer Res, 2017 23(16):4817-4830
- Clin Cancer Res, 2017 23(15):4301-4311
- Cancer Metab, 2017 5:7
- Mol Cancer Ther, 2017 16(11):2375-2386
- Sci Rep, 2017 7(1):8027
- PLoS One, 2017 12(2):e0173013
- J Pharmacol Exp Ther, 2017 363(1):20-34
- Leuk Lymphoma, 2017 58(12):2916-2925
- EMBO J, 2016 35(23):2602-2613
- Leukemia, 2016 30(1):104-11
- Proc Natl Acad Sci U S A, 2016 113(46):13162-13167
- Cardiovasc Res, 2016 110(2):188-99
- Cancer Lett, 2016 382(1):1-10
- Matrix Biol, 2016 55:22-34
- PLoS Pathog, 2016 12(10):e1005929
- Bioinformatics, 2016 32(12):i253-i261
- Oncotarget, 2016 7(47):77326-77341
- Oncotarget, 2016 7(25):38523-38538
- Oncotarget, 2016 7(4):4454-67
- Oncotarget, 2016 7(2):1598-607
- Oncotarget, 2016 7(29):45214-45224
- Oncotarget, 2016 7(48):78883-78895
- PLoS Genet, 2016 12(9):e1006279
- Horm Cancer, 2016 7(5-6):345-355
- Leuk Lymphoma, 2016 57(7):1677-86
- Biomaterials, 2015 73:70-84
- Leukemia, 2015 29(6):1390-401
- Leukemia, 2015 29(3):727-38
- Br J Haematol, 2015 171(3):378-86
- J Clin Endocrinol Metab, 2015 100(5):E697-709
- Oncotarget, 2015 6(19):17532-42
- Oncotarget, 2015 6(10):8418-29
- PLoS One, 2015 10(3):e0119546
- Med Oncol, 2015 32(4):538
- Chem Biol, 2015 22(6):755-63
- Chem Biol, 2015 10.1016/j.chembiol.2015.01.004
- Sci Transl Med, 2014 6(250):250ra112
- J Clin Invest, 2014 124(12):5263-74
- Leukemia, 2014 28(2):457-60.
- Cancer Res, 2014 74(16):4458-69
- Cancer Lett, 2014 343(2):286-94
- Matrix Biol, 2014 35:215-22
- Br J Haematol, 2014 166(4):529-39
- J Virol, 2014 87(23):13035-41
- Oncotarget, 2014 5(14):5637-50
- Mol Cell Biol, 2014 34(18):3421-34
- J Cancer, 2014 4(8):614-25
- Am J Physiol Regul Integr Comp Physiol, 2014 307(11):R1330-7
- Cancer Biol Ther, 2014 15(12):1646-57
- Leuk Res, 2014 38(8):970-6
- J Med Chem, 2013 56(3):1262-75
化学信息&溶解度
分子量 | 719.91 |
分子式 | C40H57N5O7 |
CAS号 | 868540-17-4 |
Smiles | CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 138.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 50 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 138.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 50 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 138.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 138.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 138.9 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
30%PEG300
2%TWEEN80
66%ddH2O
浓度:1mg/ml
(1.39mM)
操作示例:以 1 mL 工作液为例,取20 μL 50mg/ml的澄清DMSO储备液加到300 μL PEG300中,混合均匀使其澄清;向上述体系中加入20 μL Tween80,混合均匀使其澄清;然后继续加入660 μL ddH2O定容至1mL。工作液请现配现用!
|
|
2%DMSO
30%PEG300
2%Tween80
66%ddH2O
浓度:1mg/ml
(1.39mM)
操作示例:以 1 mL 工作液为例,取20μL50mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入20μLTween80,混合均匀使其澄清;然后继续加入660μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。